Bradley Pharmaceuticals
Bradley Pharmaceuticals was a pharmaceutical company based in the United States. It was founded in 1985 by Daniel Glassman, a former pharmaceutical sales representative. The company was listed on the New York Stock Exchange under the ticker symbol "BDY". Bradley Pharmaceuticals primarily focused on the development and marketing of dermatology and gastroenterology products.
History[edit]
Bradley Pharmaceuticals was established in 1985 by Daniel Glassman. The company started with a focus on niche therapeutic markets, particularly dermatology and gastroenterology. Over the years, Bradley Pharmaceuticals expanded its product portfolio through a combination of internal development and acquisitions.
In 2000, Bradley Pharmaceuticals acquired Doak Dermatologics, a company specializing in dermatology products. This acquisition significantly expanded Bradley's dermatology product line.
In 2005, Bradley Pharmaceuticals acquired A. Aarons Inc., a company that specialized in generic prescription pharmaceuticals. This acquisition allowed Bradley to expand into the generic pharmaceutical market.
In 2008, Bradley Pharmaceuticals was acquired by Nycomed, a Swiss pharmaceutical company. The acquisition was valued at approximately $346 million.
Products[edit]
Bradley Pharmaceuticals developed and marketed a wide range of products, primarily in the fields of dermatology and gastroenterology. Some of their notable products included Zoderm, a prescription acne treatment, and AnaMantle, a hemorrhoid treatment.
Legacy[edit]
Bradley Pharmaceuticals left a significant impact on the pharmaceutical industry. The company's focus on niche markets allowed it to develop and market products that addressed specific patient needs. This strategy proved successful, as evidenced by the company's growth and eventual acquisition by Nycomed.
See also[edit]
This article is a pharmacology-related stub. You can help WikiMD by expanding it!
-
Logo of Bradley Pharmaceuticals
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
